Clinical trial tracker

Clinical trial tracker

Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.

Reset

134 registered trials, newest registry update first.

TrialCompoundPhaseStatusSponsorEnrolledPrimary completionRegistry updated
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
NCT07785934
UBT251Phase 1RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.48Dec 2026Aug 25, 2026
Safety and Efficacy of J147 in Acute Ischemic Stroke
NCT07430917
J-147Phase 2RecruitingAbrexa Pharmaceuticals, Inc.196Mar 1, 2028Aug 24, 2026
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
RetatrutidePhase 3CompletedEli Lilly and Company2,335Apr 6, 2026Aug 21, 2026
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
LY4086940Phase 1CompletedEli Lilly and Company219Aug 5, 2026Aug 19, 2026
AT1001 for the Treatment of Long COVID
NCT05747534
LarazotidePhase 2CompletedMassachusetts General Hospital107Jun 18, 2026Aug 18, 2026
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
NCT07710768
UBT251Phase 1RecruitingNovo Nordisk A/S44Apr 7, 2027Aug 18, 2026
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity
NCT07400679
BerobenatidePhase 1CompletedPfizer48Jul 2, 2026Aug 17, 2026
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
NCT05371496
SemaglutidePhase 4CompletedMayo Clinic81Jul 17, 2026Aug 14, 2026
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528
SurvodutidePhase 3CompletedBoehringer Ingelheim755Dec 12, 2025Aug 6, 2026
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642
CagrilintidePhase 3Active not recruitingNovo Nordisk A/S300May 11, 2027Aug 6, 2026
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
NCT06987513
PemvidutidePhase 2CompletedAltimmune, Inc.100Jul 30, 2026Jul 31, 2026
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
RetatrutidePhase 3CompletedEli Lilly and Company1,152Jun 16, 2026Jul 30, 2026
Kisspeptin Administration Subcutaneously to Patients With IHH
NCT05896293
Kisspeptin-10Phase 2RecruitingStephanie B. Seminara, MD36May 2028Jul 13, 2026
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity
NCT07508241
BerobenatidePhase 1Active not recruitingPfizer22Jan 27, 2027Jul 9, 2026
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
NCT05616013
BimagrumabPhase 2CompletedEli Lilly and Company507May 16, 2024Jul 8, 2026
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540
CagrilintidePhase 3CompletedNovo Nordisk A/S2,734Nov 19, 2025Jul 8, 2026
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523
EloralintidePhase 2CompletedEli Lilly and Company263May 30, 2025Jun 24, 2026
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415
RetatrutidePhase 3Active not recruitingEli Lilly and Company600Oct 2028Jun 9, 2026
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553
Taldefgrobep alfaPhase 3Active not recruitingBiohaven Pharmaceuticals, Inc.269Sep 25, 2024Jun 1, 2026
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728
BimagrumabPhase 2Active not recruitingEli Lilly and Company252Jan 16, 2026May 26, 2026
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT06309992
SurvodutidePhase 3CompletedBoehringer Ingelheim218Oct 9, 2025Apr 30, 2026
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
NCT07519135
BerobenatidePhase 1RecruitingPfizer26Jul 9, 2027Apr 23, 2026
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
NCT07395687
UBT251Phase 2RecruitingNovo Nordisk A/S333Jan 14, 2027Apr 21, 2026
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
VK2735Phase 3Active not recruitingViking Therapeutics, Inc.1,100Jul 1, 2027Apr 7, 2026
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
NCT07505745
MOTS-cPhase 2RecruitingHudson Biotech120Feb 14, 2027Apr 1, 2026
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
NCT06662539
PetrelintidePhase 2CompletedZealand Pharma493Sep 30, 2025Mar 23, 2026
Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT07281495
Taldefgrobep alfaPhase 2Active not recruitingBiohaven Therapeutics Ltd.150Sep 2026Mar 20, 2026
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
NCT06200467
SurvodutidePhase 1CompletedBoehringer Ingelheim110Oct 22, 2025Mar 13, 2026
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
NCT06352411
SurvodutidePhase 1CompletedBoehringer Ingelheim42Sep 16, 2025Mar 13, 2026
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515
SurvodutidePhase 3CompletedBoehringer Ingelheim726Dec 2, 2025Mar 12, 2026
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660
RetatrutidePhase 3CompletedEli Lilly and Company537Jan 22, 2026Mar 5, 2026
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
CagrilintidePhase 3CompletedNovo Nordisk A/S809Dec 8, 2025Feb 6, 2026
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
NCT06445075
ApitegromabPhase 2CompletedScholar Rock, Inc.102Mar 4, 2025Jan 23, 2026
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
NCT05156320
ApitegromabPhase 3CompletedScholar Rock, Inc.188Dec 18, 2024Jan 22, 2026
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
RetatrutidePhase 3CompletedEli Lilly and Company445Nov 14, 2025Jan 21, 2026
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
NCT04982575
CagrilintidePhase 2CompletedNovo Nordisk A/S92Jul 7, 2022Dec 23, 2025
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
NCT05814107
CT-996Phase 1CompletedCarmot Australia First Pty Ltd94Nov 7, 2025Nov 28, 2025
VK2735 for Weight Management Phase 3
NCT07104500
VK2735Phase 3Active not recruitingViking Therapeutics, Inc.4,500Jul 1, 2027Nov 24, 2025
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT05016882
CagrilintidePhase 2CompletedNovo Nordisk A/S698Dec 17, 2024Nov 19, 2025
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
NCT05633966
Kisspeptin-10Phase 1CompletedStephanie B. Seminara, MD13Aug 31, 2025Oct 3, 2025
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349
BimagrumabPhase 2WithdrawnEli Lilly and Company–Jun 10, 2025Sep 24, 2025
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
NCT05896384
SurvodutidePhase 1CompletedBoehringer Ingelheim32Feb 14, 2025Apr 16, 2025
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273
SurvodutidePhase 2CompletedBoehringer Ingelheim295Nov 9, 2023Dec 3, 2024
A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
NCT05298306
AOD-9604Phase 1CompletedLateral Pharma Pty Ltd26May 12, 2023Nov 27, 2024
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
NCT05296733
SurvodutidePhase 1CompletedBoehringer Ingelheim82Dec 29, 2023Aug 15, 2024
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT03856047
CagrilintidePhase 2CompletedNovo Nordisk A/S706Mar 2, 2020Jul 5, 2024
AT1001 for the Treatment of COVID-19 Related MIS-C
NCT05022303
LarazotidePhase 2TerminatedMassachusetts General Hospital12May 15, 2024Jun 13, 2024
A Study of LY3841136 in Healthy and Overweight Participants
NCT05295940
EloralintidePhase 1CompletedEli Lilly and Company148Jan 25, 2024Apr 1, 2024
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377
SurvodutidePhase 2CompletedBoehringer Ingelheim387Sep 15, 2022Nov 2, 2023
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
NCT02354781
Follistatin 344Phase 1 / Phase 2CompletedJerry R. Mendell3Nov 2017Oct 11, 2023

← Newer Page 2 of 3 Older →

Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.